PLAY PODCASTS
Why has this Alzheimer’s drug not been approved?

Why has this Alzheimer’s drug not been approved?

Lunchtime Live · Newstalk

April 8, 202520m 4s

Audio is streamed directly from the publisher (bauernordic-pods.sharp-stream.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

A drug designed to slow down cognitive decline in Alzheimer’s, Kisunla, has so far been turned down for approval by the EU.

This has led to huge frustration amongst Alzheimer’s experts that hailed the drug as a game-changer.

Joining guest host Anna Daly to discuss is Dr. Laura O’Philbin, Research and Policy Manager at the Alzheimer Society of Ireland, Professor Sean Kennelly, Clinical Director of the Institute of Memory and Cognition in Tallaght University Hospital and listeners who have been personally impacted by the disease.

Image: Eli Lilly